The current landscape of gastric cancer and gastroesophageal junction cancer diagnosis and treatment in China: a comprehensive nationwide cohort analysis
Abstract Background Gastric cancer is the fifth most common cancer globally and is associated with significant morbidity and mortality. Despite its alarming prevalence, limited comparative evidence exists on its treatment efficacy and prognosis across diverse China populations. Methods To address th...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-04-01
|
| Series: | Journal of Hematology & Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13045-025-01698-y |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850145009569890304 |
|---|---|
| author | Yang Chen Keren Jia Yi Xie Jiajia Yuan Dan Liu Lei Jiang Haoxin Peng Jia Zhong Jian Li Xiaotian Zhang Lin Shen |
| author_facet | Yang Chen Keren Jia Yi Xie Jiajia Yuan Dan Liu Lei Jiang Haoxin Peng Jia Zhong Jian Li Xiaotian Zhang Lin Shen |
| author_sort | Yang Chen |
| collection | DOAJ |
| description | Abstract Background Gastric cancer is the fifth most common cancer globally and is associated with significant morbidity and mortality. Despite its alarming prevalence, limited comparative evidence exists on its treatment efficacy and prognosis across diverse China populations. Methods To address this, our study used a large-scale dataset from the National Cancer Information Database, including data from 220,304 patients from 53 leading hospitals across 27 provinces in China. Results From 2017 to 2023, early-stage (Stages I-II) gastric cancer diagnoses increased to 35.63% of all cancer cases. Our study evaluated the neoadjuvant treatment strategies, adjuvant post-operative therapy, first- and second-line management for progressive stages, alongside current gastric cancer treatment guidelines in China. Notably, immunotherapy accounted for 16.17% and 23.28% of first- and second-line treatments for late-stage gastric cancers, and 14.56% and 5.00% for neoadjuvant and adjuvant therapies, respectively. Analysis of survival rates revealed that the 1-, 2-, 3-, 4-, and 5-year survival rates were 74.07%, 54.89%, 44.21%, 37.97%, and 33.53%, respectively. The 5-year survival rates across stages I-IV were 85.07%, 49.34%, 35.56%, and 13.15%, respectively. Conclusions These findings offer critical insights into the current state of gastric cancer treatment in China and can inform future initiatives to improve therapeutic outcomes for patients with gastric cancer. |
| format | Article |
| id | doaj-art-06d2bde240f4400aae2ca3dee7f25d9c |
| institution | OA Journals |
| issn | 1756-8722 |
| language | English |
| publishDate | 2025-04-01 |
| publisher | BMC |
| record_format | Article |
| series | Journal of Hematology & Oncology |
| spelling | doaj-art-06d2bde240f4400aae2ca3dee7f25d9c2025-08-20T02:28:11ZengBMCJournal of Hematology & Oncology1756-87222025-04-0118111410.1186/s13045-025-01698-yThe current landscape of gastric cancer and gastroesophageal junction cancer diagnosis and treatment in China: a comprehensive nationwide cohort analysisYang Chen0Keren Jia1Yi Xie2Jiajia Yuan3Dan Liu4Lei Jiang5Haoxin Peng6Jia Zhong7Jian Li8Xiaotian Zhang9Lin Shen10Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education, Beijing), Peking University Cancer Hospital and InstituteDepartment of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education, Beijing), Peking University Cancer Hospital and InstituteDepartment of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education, Beijing), Peking University Cancer Hospital and InstituteDepartment of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education, Beijing), Peking University Cancer Hospital and InstituteDepartment of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education, Beijing), Peking University Cancer Hospital and InstituteDepartment of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education, Beijing), Peking University Cancer Hospital and InstituteDepartment of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education, Beijing), Peking University Cancer Hospital and InstituteAnalysis GroupDepartment of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education, Beijing), Peking University Cancer Hospital and InstituteDepartment of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education, Beijing), Peking University Cancer Hospital and InstituteDepartment of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education, Beijing), Peking University Cancer Hospital and InstituteAbstract Background Gastric cancer is the fifth most common cancer globally and is associated with significant morbidity and mortality. Despite its alarming prevalence, limited comparative evidence exists on its treatment efficacy and prognosis across diverse China populations. Methods To address this, our study used a large-scale dataset from the National Cancer Information Database, including data from 220,304 patients from 53 leading hospitals across 27 provinces in China. Results From 2017 to 2023, early-stage (Stages I-II) gastric cancer diagnoses increased to 35.63% of all cancer cases. Our study evaluated the neoadjuvant treatment strategies, adjuvant post-operative therapy, first- and second-line management for progressive stages, alongside current gastric cancer treatment guidelines in China. Notably, immunotherapy accounted for 16.17% and 23.28% of first- and second-line treatments for late-stage gastric cancers, and 14.56% and 5.00% for neoadjuvant and adjuvant therapies, respectively. Analysis of survival rates revealed that the 1-, 2-, 3-, 4-, and 5-year survival rates were 74.07%, 54.89%, 44.21%, 37.97%, and 33.53%, respectively. The 5-year survival rates across stages I-IV were 85.07%, 49.34%, 35.56%, and 13.15%, respectively. Conclusions These findings offer critical insights into the current state of gastric cancer treatment in China and can inform future initiatives to improve therapeutic outcomes for patients with gastric cancer.https://doi.org/10.1186/s13045-025-01698-yGastric cancerStage at diagnosisTreatment regimenImmunotherapySurvival |
| spellingShingle | Yang Chen Keren Jia Yi Xie Jiajia Yuan Dan Liu Lei Jiang Haoxin Peng Jia Zhong Jian Li Xiaotian Zhang Lin Shen The current landscape of gastric cancer and gastroesophageal junction cancer diagnosis and treatment in China: a comprehensive nationwide cohort analysis Journal of Hematology & Oncology Gastric cancer Stage at diagnosis Treatment regimen Immunotherapy Survival |
| title | The current landscape of gastric cancer and gastroesophageal junction cancer diagnosis and treatment in China: a comprehensive nationwide cohort analysis |
| title_full | The current landscape of gastric cancer and gastroesophageal junction cancer diagnosis and treatment in China: a comprehensive nationwide cohort analysis |
| title_fullStr | The current landscape of gastric cancer and gastroesophageal junction cancer diagnosis and treatment in China: a comprehensive nationwide cohort analysis |
| title_full_unstemmed | The current landscape of gastric cancer and gastroesophageal junction cancer diagnosis and treatment in China: a comprehensive nationwide cohort analysis |
| title_short | The current landscape of gastric cancer and gastroesophageal junction cancer diagnosis and treatment in China: a comprehensive nationwide cohort analysis |
| title_sort | current landscape of gastric cancer and gastroesophageal junction cancer diagnosis and treatment in china a comprehensive nationwide cohort analysis |
| topic | Gastric cancer Stage at diagnosis Treatment regimen Immunotherapy Survival |
| url | https://doi.org/10.1186/s13045-025-01698-y |
| work_keys_str_mv | AT yangchen thecurrentlandscapeofgastriccancerandgastroesophagealjunctioncancerdiagnosisandtreatmentinchinaacomprehensivenationwidecohortanalysis AT kerenjia thecurrentlandscapeofgastriccancerandgastroesophagealjunctioncancerdiagnosisandtreatmentinchinaacomprehensivenationwidecohortanalysis AT yixie thecurrentlandscapeofgastriccancerandgastroesophagealjunctioncancerdiagnosisandtreatmentinchinaacomprehensivenationwidecohortanalysis AT jiajiayuan thecurrentlandscapeofgastriccancerandgastroesophagealjunctioncancerdiagnosisandtreatmentinchinaacomprehensivenationwidecohortanalysis AT danliu thecurrentlandscapeofgastriccancerandgastroesophagealjunctioncancerdiagnosisandtreatmentinchinaacomprehensivenationwidecohortanalysis AT leijiang thecurrentlandscapeofgastriccancerandgastroesophagealjunctioncancerdiagnosisandtreatmentinchinaacomprehensivenationwidecohortanalysis AT haoxinpeng thecurrentlandscapeofgastriccancerandgastroesophagealjunctioncancerdiagnosisandtreatmentinchinaacomprehensivenationwidecohortanalysis AT jiazhong thecurrentlandscapeofgastriccancerandgastroesophagealjunctioncancerdiagnosisandtreatmentinchinaacomprehensivenationwidecohortanalysis AT jianli thecurrentlandscapeofgastriccancerandgastroesophagealjunctioncancerdiagnosisandtreatmentinchinaacomprehensivenationwidecohortanalysis AT xiaotianzhang thecurrentlandscapeofgastriccancerandgastroesophagealjunctioncancerdiagnosisandtreatmentinchinaacomprehensivenationwidecohortanalysis AT linshen thecurrentlandscapeofgastriccancerandgastroesophagealjunctioncancerdiagnosisandtreatmentinchinaacomprehensivenationwidecohortanalysis AT yangchen currentlandscapeofgastriccancerandgastroesophagealjunctioncancerdiagnosisandtreatmentinchinaacomprehensivenationwidecohortanalysis AT kerenjia currentlandscapeofgastriccancerandgastroesophagealjunctioncancerdiagnosisandtreatmentinchinaacomprehensivenationwidecohortanalysis AT yixie currentlandscapeofgastriccancerandgastroesophagealjunctioncancerdiagnosisandtreatmentinchinaacomprehensivenationwidecohortanalysis AT jiajiayuan currentlandscapeofgastriccancerandgastroesophagealjunctioncancerdiagnosisandtreatmentinchinaacomprehensivenationwidecohortanalysis AT danliu currentlandscapeofgastriccancerandgastroesophagealjunctioncancerdiagnosisandtreatmentinchinaacomprehensivenationwidecohortanalysis AT leijiang currentlandscapeofgastriccancerandgastroesophagealjunctioncancerdiagnosisandtreatmentinchinaacomprehensivenationwidecohortanalysis AT haoxinpeng currentlandscapeofgastriccancerandgastroesophagealjunctioncancerdiagnosisandtreatmentinchinaacomprehensivenationwidecohortanalysis AT jiazhong currentlandscapeofgastriccancerandgastroesophagealjunctioncancerdiagnosisandtreatmentinchinaacomprehensivenationwidecohortanalysis AT jianli currentlandscapeofgastriccancerandgastroesophagealjunctioncancerdiagnosisandtreatmentinchinaacomprehensivenationwidecohortanalysis AT xiaotianzhang currentlandscapeofgastriccancerandgastroesophagealjunctioncancerdiagnosisandtreatmentinchinaacomprehensivenationwidecohortanalysis AT linshen currentlandscapeofgastriccancerandgastroesophagealjunctioncancerdiagnosisandtreatmentinchinaacomprehensivenationwidecohortanalysis |